Compare Moderna, Inc. (MRNA) vs Sun Life Financial Inc. Common Stock (SLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sun Life Financial Inc. Common Stock — how do they compare? Moderna, Inc. trades at $223.24 (market cap $86.33B), while Sun Life Financial Inc. Common Stock trades at $77.62 (market cap $43.10B). The key difference: Moderna, Inc. is far larger — about 2× Sun Life Financial Inc. Common Stock's market cap, and Sun Life Financial Inc. Common Stock pays a 3.48% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Sun Life Financial Inc. Common Stock for 0 Days on average.
| MRNA | SLF | |
|---|---|---|
Market Cap | $86.33B | $43.10B |
Volume | 13,361,426 | 448,420 |
Sector | Health | Financials |
52-Week High | $226.30 | $84.07 |
52-Week Low | $22.36 | $57.60 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $82.48B | $44.83B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal and recent Nasdaq-100 inclusion driving momentum. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with a net income margin of -142.58% and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock's 500% rally in 2026 has pushed valuations to elevated levels with a P/S of 38.5, creating divergence between technical strength and financial performance.
The outlook remains polarized with Nasdaq inclusion providing institutional support but valuation concerns capping upside. Investment opportunity lies in the cancer vaccine pipeline, while risks include sustained profitability challenges and competitive pressures. Analyst consensus at $115.70 suggests significant downside from current levels, with only 28% recommending buy ratings amid ongoing operational cash flow deficits.
Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.
The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sun Life Financial Inc. Common Stock
Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.
Read more on SLF →
